GlassScriptPhysician profile
Priya Rudolph
NPI 1871587113
$744,553.75
in general payments reported to CMS, 2019-2025
74 companies · $147K in 2025
The $147K reported for 2025 was more than what 99% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43K · 2020: $29K · 2021: $55K · 2022: $78K · 2023: $219K · 2024: $173K · 2025: $147K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $296K · Consulting Fee: $156K · Travel and Lodging: $70K · Food and Beverage: $16K · Education: $464 · Honoraria: $233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $296,222.48 |
| Consulting Fee | $155,849.80 |
| Travel and Lodging | $69,940.08 |
| Food and Beverage | $15,841.59 |
| Education | $463.61 |
| Honoraria | $233.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $146,659.71 | 2019-2025 | |
| Daiichi Sankyo INC. | $128,038.93 | 2021-2025 | Enhertu, Datroway, Vanflyta |
| Astrazeneca Pharmaceuticals LP | $126,566.61 | 2019-2025 | Calquence, Enhertu, Datroway |
| Gilead Sciences, INC. | $59,983.33 | 2021-2025 | Trodelvy |
| Puma Biotechnology, INC. | $56,155.55 | 2020-2025 | Nerlynx |
| Stemline Therapeutics INC. | $52,208.21 | 2023-2025 | Orserdu, Elzonris |
| Seagen INC. | $29,024.01 | 2021-2023 | Tivdak, Tukysa |
| E.R. Squibb & Sons, L.L.C. | $19,409.99 | 2019-2025 | Opdualag |
| Glaxosmithkline, LLC. | $11,859.44 | 2020-2025 | Ojjaara, Blenrep |
| Janssen Scientific Affairs, LLC | $11,294.21 | 2019-2025 | Darzalex, Rybrevant, Imbruvica |
| Incyte Corporation | $8,867.70 | 2022-2025 | Monjuvi, Jakafi, Pemazyre |
| Lilly USA, LLC | $8,601.92 | 2020-2025 | Jaypirca, Verzenio, Retevmo |
| Abbvie INC. | $7,987.96 | 2019-2025 | |
| Epizyme, INC. | $7,009.94 | 2022 | |
| Btg International INC. | $7,000.00 | 2024-2025 |
Show all 74 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cti Biopharma Corp. | $6,975.00 | 2022 | |
| Morphosys, US INC. | $6,524.54 | 2021-2024 | Monjuvi |
| Emd Serono, INC. | $5,922.23 | 2021-2025 | Bavencio |
| Ipsen Biopharmaceuticals, INC | $4,845.20 | 2019-2024 | Onivyde |
| Avyxa Pharma, LLC | $4,072.03 | 2025 | |
| Genzyme Corporation | $4,059.87 | 2021-2025 | |
| Amag Pharmaceuticals, INC. | $3,996.15 | 2019 | |
| Mylan Institutional INC. | $3,817.39 | 2019 | |
| Genentech USA, INC. | $3,106.28 | 2024-2025 | Itovebi, Tecentriq, Phesgo |
| Celgene Corporation | $3,022.73 | 2023-2025 | Opdivo, Abecma, Pomalyst |
| Array Biopharma INC | $2,030.08 | 2021-2025 | Braftovi, Mektovi, Lorbrena |
| Adc Therapeutics America, INC. | $2,000.00 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,912.08 | 2021-2025 | |
| Karyopharm Therapeutics INC. | $1,604.67 | 2021-2025 | Xpovio |
| Tg Therapeutics, INC. | $1,526.25 | 2021 | |
| Blueprint Medicines Corporation | $1,215.44 | 2021-2024 | Ayvakit |
| Coherus Oncology, INC. | $1,010.47 | 2021-2024 | |
| Astellas Pharma US INC | $695.60 | 2021-2025 | Xtandi, Xospata, Vyloy |
| Novartis Pharmaceuticals Corporation | $522.76 | 2019-2025 | |
| Immunocore Limited | $500.00 | 2025 | |
| Janssen Biotech, INC. | $435.91 | 2019-2025 | Rybrevant, Darzalex, Erleada |
| Sobi, INC | $322.39 | 2024-2025 | |
| Pharmaessentia USA Corporation | $317.36 | 2023-2025 | Besremi |
| Adaptive Biotechnologies Corporation | $311.99 | 2021-2025 | Clonoseq |
| Genentech, INC. | $304.79 | 2019-2025 | Columvi |
| Alexion Pharmaceuticals, INC. | $297.25 | 2019-2025 | Ultomiris |
| Tempus Ai, INC | $266.00 | 2024-2025 | Xt Cdx |
| Amgen INC. | $256.14 | 2023-2025 | Blincyto, Imdelltra (Amg 757), Blincyto |
| Takeda Pharmaceuticals U.S.A., INC. | $190.38 | 2019-2024 | Ninlaro, Alunbrig, Iclusig |
| Jazz Pharmaceuticals INC. | $180.33 | 2024-2025 | |
| Caris Mpi, INC. | $170.95 | 2025 | Mi Cancer Seek |
| Merck Sharp & Dohme LLC | $145.26 | 2024 | Keytruda, Welireg |
| Exelixis INC. | $123.60 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $122.03 | 2021-2025 | Libtayo, Lynozyfic |
| Beigene USA, INC. | $101.03 | 2020-2025 | Brukinsa |
| Eisai INC. | $99.91 | 2024-2025 | |
| Corcept Therapeutics | $95.08 | 2024-2025 | Korlym |
| Alnylam Pharmaceuticals INC. | $62.38 | 2022-2025 | Givlaari |
| Pharmacyclics LLC, An Abbvie Company | $61.12 | 2023 | Imbruvica, Epkinly |
| Eusa Pharma (US) LLC | $60.06 | 2019 | |
| Beone Medicines USA, INC. | $52.38 | 2025 | Brukinsa, Tevimbra |
| Geron Corporation | $51.47 | 2025 | Rytelo |
| Myriad Genetic Laboratories, INC. | $50.50 | 2025 | Myrisk |
| Clovis Oncology, INC. | $48.22 | 2019 | |
| Immunogen, INC. | $47.20 | 2023 | Elahere |
| Agios Pharmaceuticals, INC. | $46.19 | 2024-2025 | Pyrukynd |
| Pharmacosmos Therapeutics INC. | $41.73 | 2025 | Monoferric |
| Tersera Therapeutics LLC | $39.85 | 2025 | Zoladex |
| Aveo Pharmaceuticals, INC. | $30.80 | 2025 | |
| Deciphera Pharmaceuticals INC. | $30.13 | 2025 | Qinlock, Romvimza |
| Ge Healthcare | $29.32 | 2025 | |
| Legend Biotech USA INC. | $24.78 | 2025 | Carvykti |
| Genmab U.S., INC. | $22.72 | 2024 | Epkinly |
| Syndax Pharmaceuticals, INC. | $19.78 | 2025 | |
| G1 Therapeutics, INC. | $18.02 | 2023 | Cosela |
| Apellis Pharmaceuticals, INC. | $15.37 | 2025 | Empaveli |
| Mirati Therapeutics, INC. | $15.32 | 2023 | Krazati |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.48 | 2025 | |
| Janssen Pharmaceuticals, INC | $6.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priya Rudolph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.